Entresto (sacubitril/valsartan) - Novartis, ROVI Pharmaceuticals Laboratories
Predicting the reduction of functional mitral regurgitation with optimized medical therapy in HFrEF patients by standard echocardiography and non-invasive pressure-volume loop model. (PubMed, Int J Cardiol) - Oct 1, 2026 - "The combined assessment of echocardiography-derived VE and LVEDVi was associated with FMR improvement in the primary model; however, VE was no longer independently associated after additional adjustment for baseline E/e'. FMR improvement was closely associated with LV reverse remodeling, although a causal direction cannot be established from this observational study." 
Journal • Cardiovascular
http://www.ncbi.nlm.nih.gov/pubmed/42815582
 
; Alberto Palazzuoli; Daniele Masarone; Erberto Carluccio; Frank Lloyd Dini; Giuseppe Dattilo; Mauro Acquaro; Michele Correale; Savina Nodari; Stefano Ghio; Valentina Mercurio
 
Oct 1, 2026
 
Prev Next